BMS cuts expectations for Opdivo/Yervoy combo

Bristol-Myers Squibb Co. (NYSE:BMY) said that it no longer plans to seek accelerated approval of Opdivo nivolumab in combination with Yervoy ipilimumab as a first-line treatment for lung cancer. The company said it based its decision on a review of available data.

BMS has said it expects data next year from the Phase III CheckMate -227 study, which is evaluating the Opdivo/Yervoy combo, Opdivo as monotherapy, and Opdivo plus chemotherapy to treat non-small cell lung cancer (NSCLC). The company told BioCentury in August 2016 that an interim analysis is built into the study's design...